Infergen Gains 12 Month Duration Of Therapy In EU, Double That In U.S.
Executive Summary
Results from an extension study of Yamanouchi's Infergen (interferon alfacon-1) support a duration of treatment over twice as long as that approved in the U.S., according to the May 5 European Public Assessment Report for the hepatitis C therapy.